AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer

Launched by AKESO · Oct 16, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new combination treatment for patients with advanced pancreatic cancer, specifically a type called metastatic pancreatic ductal adenocarcinoma. The researchers want to see if using two drugs, AK112 and Cadonilimab, along with standard chemotherapy, is safe and effective as a first treatment option for this aggressive cancer. This study is currently recruiting participants aged 18 to 75 who are in relatively good health and have not yet received other treatments for their metastatic cancer.

To be eligible for this trial, participants need to have a confirmed diagnosis of metastatic pancreatic cancer and a life expectancy of at least three months. They should also be able to participate in the study and follow all the necessary procedures. If you decide to join, you'll receive the new treatment and be closely monitored by the medical team to evaluate how well it works and its safety. This research is important because it may lead to better treatment options for people with this challenging disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Be able and willing to provide written informed consent and to comply with all requirements of study participation (including all study procedures).
• • 2. ≥18 years old and ≤ 75 years (regardless of sex).
• • 3. ECOG performance status 0-1
• • 4. Life expectancy longer than 3 months.
• • 5. Histologically or cytologically confirmed diagnosis of metastatic pancreatic ductal carcinoma (PDAC).
• • 6. No prior systemic anti-tumor therapy for metastatic PDAC.
• • 7. Adequate organ function.
• • 8. Measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
• Exclusion Criteria:
• • 1. Histological or cytological diagnosis of other pathological types.
• • 2. BRCA1/2 or PALB2 mutations.
• • 3. Participating in another clinical research.
• • 4. Active central nervous system (CNS) metastases.
• • 5. Undergoing systemic antiangiogenic therapy.
• • 6. Acute or subacute pancreatitis.
• • 7. Other known malignancies within five years.
• • 8. Active infection requiring systemic therapy.